Stock Ratings / Health Care / TRAW / dividends

AZTR (41) IMNN (42) NCNA (56) XTLB (47) ⌘ Pro Terminal →

Traws Pharma Inc. (TRAW) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Does TRAW pay a dividend and is it safe?

Traws Pharma Inc. (TRAW) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$0.30 -16.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Traws Pharma Inc. (TRAW) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $4.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TRAW)Realized 20D OHLCV Swing Band: ±12.5%

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (16.3% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $45,269

Est. Year-10 Shareholder Yield: $815/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.6K

Yr 1

$13.5K

Yr 2

$15.7K

Yr 3

$18.3K

Yr 4

$21.3K

Yr 5

$24.7K

Yr 6

$28.8K

Yr 7

$33.5K

Yr 8

$38.9K

Yr 9

$45.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TRAW)

✓Walkthrough of TRAW's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TRAW // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -79.02%📐 HORIZONTAL RANGE

2026-10-30O $0.31H $0.31L $0.29C $0.30VOL 198.7K

RES: $0.78SUP: $0.01SMA50: $0.49SMA200: $1.17

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TRAW Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TRAW Butterfly Map → + Track TRAW →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TRAW today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TRAW. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TRAW today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TRAW)

Health Care Rank #733 of 1016 ⚔️ AZTR vs TRAW Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TRAW vs. AZTR, IMNN, NCNA, XTLB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Traws Pharma Inc. (TRAW) ranks #733 by composite RQD confidence (38/100, grade D-) and #953 by equity capitalization ($4.6M). Within this direct 5-issuer industry benchmark cohort, TRAW leads on earnings valuation at N/A trailing P/E, while TRAW leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. NCNA currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with TRAW at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TRAW ACTIVE Traws Pharma Inc.	D-	38/100	—	—	-35.0%	-16.34%	$4.6M	Benchmark Subject
AZTR Azitra Inc	D-	41/100	—	—	-35.0%	-16.31%	$4.6M	/aztr-vs-traw →
IMNN Imunon Inc.	D-	42/100	—	—	-35.0%	+0.35%	$4.7M	/imnn-vs-traw →
NCNA NuCana plc	D+	56/100	—	—	—	-3.26%	$4.3M	/ncna-vs-traw →
XTLB XTL Biopharmaceuticals Ltd.	D	47/100	—	—	—	-12.44%	$4.3M	/xtlb-vs-traw →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001130598

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Traws Pharma Inc. (TRAW) reported GAAP revenue of $2.8M (+1134.5% vs. FY2024 revenue of $226.0K , and +1134.5% cumulative change since FY2023) , GAAP net income of $9.2M, operating cash flow of -$18.2M, and free cash flow of -$18.2M (+39.0% YoY). On the balance sheet, TRAW closed FY2025 with $10.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.8M	$9.2M	-$18.2M	-$18.2M	$10.6M	—
FY2024 (FY)	2024-12-31	$226.0K	-$166.5M	-$29.8M	-$29.8M	$25.0M	—
FY2023 (FY)	2023-12-31	$226.0K	-$18.9M	-$17.9M	-$17.9M	—	—

3. TRAW Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TRAW stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Traws Pharma Inc. (NASDAQ: TRAW) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.30 (-16.34% 1D, market cap $4.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TRAW ranks #733 in composite RQD confidence.

How does TRAW compare to AZTR and IMNN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TRAW carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AZTR (Azitra Inc) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $4.6M) and IMNN (Imunon Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M). Among the 5-stock peer group, TRAW leads on earnings multiple (N/A) while TRAW leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TRAW?

Per TRAW's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001130598), Traws Pharma Inc. generated $2.8M in revenue (+1134.5% YoY), $9.2M in net income, and -$18.2M in free cash flow against $10.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TRAW trading relative to its 50-day, 200-day, and 52-week technical levels?

TRAW last traded at $0.30 (-16.34% on volume of 718,988 shares), positioning the stock -38.78% below its 50-day simple moving average ($0.49) and -74.36% below its 200-day simple moving average ($1.17). Across its 52-week range of $0.29 to $3.23, TRAW sits at the 0.3% percentile with a 14-day RSI of 25.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.34).

TRAW Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does TRAW pay a dividend and is it safe?

Traws Pharma Inc. (TRAW) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: TRAW RQD Cockpit TRAW 12M Forecast TRAW Earnings & Move TRAW Dividends & DRIP TRAW Insiders & 13F TRAW Whale Options TRAW Profit Sankey TRAW News & Why